11th August, 2020

To,	To,
BSE Limited,	The Manager,
25, P. J. Towers,	Listing Department,
Dalal Street,	National Stock Exchange of India Ltd.,
Mumbai – 400 001	Exchange Plaza, Bandra Kurla Complex,
Ref: Company Scrip Code: 532834	Bandra (East), Mumbai‐ 400051
	Ref: Symbol: CAMLINFINE Series: EQ

Sub: Intimation pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ‐ ("SEBI LODR")

This is in continuation to our disclosure dated August 6, 2020 in relation to the conference call with various domestic and international investors and analysts organized by Dolat Analysis & Research Themes (DART) to discuss the financial results of the Company for the quarter ended June 30, 2020 (Q1) on August 10, 2020, please find enclosed herewith the investor presentation made for the aforesaid call.

It is clarified that the presentation and the information contained therein does not constitute or form part of an invitation or solicitation to offer to purchase or subscribe to any securities of the Company in any jurisdiction. This presentation has been prepared for information purposes only. The information contained in the investor presentation is not to be taken as any recommendation made by the Company or any other person to enter into any agreement with regard to any investment.

We request you to take the above on record and the same be treated as compliance under the applicable Regulations of SEBI LODR.

Thanking You, Encl.: a/a. For Camlin Fine Sciences Limited

Mandar Godbole Company Secretary & Compliance Officer

EARNINGS PRESENTATION

Q1-FY21

Company Overview

Camlin Fine Sciences Limited (CFS), formed in 2006 after demerging the fine chemical business from Camlin Ltd., is a vertically integrated company engaged in research, development, manufacturing, commercializing and marketing of specialty chemicals and blends, which are used in a wide array of sectors.
CFS is global leading producer of food antioxidants, such as TBHQ & BHA, and the world's 3 rd largest producer of Vanillin.

FY20 Business Mix (Revenue Share %)

Shelf Life Solutions (54%) : Includes Anti-oxidants, Blends and Additives
Performance Chemicals (24%): Includes Specialty Chemicals
Aroma Chemicals (20%): Includes Vanillin and Ethyl Vanillin

Manufacturing Facilities, R&D Centres and Application Labs

R&D Centres at Tarapur(India) and Ravenna (Italy)

Application Labs in India, Brazil, North America, Italy and Mexico

* Excluding Other Income &Foreign Exchange Fluctuation Gain/ (Loss) # Including non controlling interest

One of the fewvertically andbackwardintegrated players	Leading Manufacturers ofAntioxidants in the worldwith more than 30 years ofexperience	rd3largest producer ofVanillin in the world
Serving more than 80countries with over100 products	Preferred Partner formanufacturing customizedproducts	Strategic move to startblends which have highermargins
5 ManufacturingFacilities, 2 R&DCentres and 5Application Labs	Global expertise, localsolutions	Strong managementteam with experiencedindustry professionals

4 About the Company

In 2006, Camlin Fine Sciences Limited (CFS) was formed after de-merging (mirror shareholding) the fine chemical business from Camlin Ltd.
The Company has over 30 years of experience providing innovative solutions with a competitive advantage in fine sciences.
CFS is a vertically integrated company, engaged in research, development, manufacturing, commercializing and marketing of specialty chemicals and blends, which are used in a wide array of sectors.
- o Food, feed, animal and pet nutrition
  - o Flavours & Fragrance
  - o Pharma
  - o Agro Chemicals
o Petro chemicals
- o Dyes and Pigments
o Polymers
o Bio Diesel
CFS categorizes their business into 3 different verticals based on their product portfolio, namely: Shelf-Life Solutions (which include anti-oxidants, its blends and additives), Performance chemicals and Aroma Chemicals.
CFS has subsidiaries in Mexico, North America, China, Europe and Brazil serving in more than 80 countries with more than 100 products and over 1,000 satisfied customers.
CFS markets its products in Europe, Asia Pacific (including India), North Africa, Middle East, South, Central and North America.

Q1-FY21 FINANCIAL OVERVIEW

Q1-FY21 Financial Highlights (Standalone):

Turnover: INR 1,212 Mn
EBITDA: INR 163 Mn
EBITDA Margin : 13.45%
Adjusted EBITDA*: INR 163 Mn
PBT: INR 51 Mn
PAT: INR 38 Mn
PAT Margins: 3.14%

Q1-FY21 Financial Highlights (Consolidated):

Turnover: INR 3,057 Mn
EBITDA: INR 510 Mn
EBITDA Margin: 16.68%
Adjusted EBITDA*: INR 543 Mn
PBT: INR 315 Mn
PAT: INR 206 Mn
PAT Margins: 6.74%

Key Highlights:

Standalone & Consolidated

Robust growth in sales in all sectors
Margins are high due to Improved product mix
Profitability has improved due to Effective expense management

7 Q1-FY21 Standalone Income Statement (Ind-AS)

Income Statement (Mn)	Q1-FY21	Q1-FY20	Y-o-Y	Q4-FY20	Q-o-Q
Operational Revenue	1,212	1,436	(15.6)%	1,395	(13.1)%
Total Expenses	1,049	1,308	(19.8)%	1,256	(16.5)%
Operational EBITDA	163	128	27.3%	139	17.3%
Operational EBITDA Margins (%)	13.45%	8.91%	454 Bps	9.96%	349 Bps
Adjusted EBITDA*	163	137	18.98%	139	17.27%
Adjusted EBITDA Margins(%)	13.45%	9.54%	391 Bps	9.96%	349 Bps
Other Income	10	10	NA	157	(93.6)%
Depreciation	31	28	10.7%	30	3.3%
Finance Cost	86	55	56.4%	68	26.5%
Exceptional Items	5	31	(83.9)%	-	NA
PBT	51	24	112.5%	198	(74.2)%
Tax	13	8	62.5%	33	(60.6)%
Profit After tax	38	16	137.5%	165	(77.0)%
PAT Margins (%)	3.14%	1.11%	203 Bps	11.83%	(869) Bps
Other Comprehensive Income	-	(1)	NA	4	NA
Total Comprehensive Income	38	15	153.3%	169	(77.5)%
Diluted EPS (INR)	0.31	0.13	138.5%	1.36	(77.2)%

* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)

8 Q1-FY21 Consolidated Income Statement (Ind-AS)

Income Statement (INR Mn)	Q1-FY21	Q1-FY20	Y-o-Y	Q4-FY20	Q-o-Q
Operational Revenue	3,057	2,601	17.5%	2,929	4.4%
Total Expenses	2,547	2,246	13.4%	2,586	(1.5)%
Operational EBITDA	510	355	43.7%	343	48.7%
Operational EBITDA Margins (%)	16.68%	13.65%	303 Bps	11.71%	497 Bps
Adjusted EBITDA*	543	358	51.68%	343	58.31%
Adjusted EBITDA Margins (%)	17.76%	13.76%	400 Bps	11.71%	605 Bps
Other Income	5	7	(28.6)%	28	(82.1)%
Depreciation	95	76	25.0%	92	3.3%
Finance Cost	105	59	78.0%	152	(30.9)%
Share of profit/ loss of associate	-	-	NA	-	NA
PBT	315	227	38.8%	127	148.0%
Tax	109	63	73.0%	106	2.8%
Profit After Tax	206	164	25.6%	21	NA
PAT Margins (%)	6.74%	6.30%	44 Bps	0.72%	602 Bps
Other Comprehensive Income	46	1	NA	45	2.2%
Total Comprehensive Income	252	165	52.7%	66	NA
Diluted EPS (INR)	1.27	1.28	(0.8)%	0.22	NA

* EBITDA after adjusting Foreign Exchange Fluctuation Gain/ (Loss)

COUNTRY OVERVIEW

R&D Centre at Tarapur that has developed many new Diphenol-downstream products
Shelf Life Solutions Development, Testing and Applications Lab at Mumbai that works on testing food formulations and blends for the food, pet food and animal nutrition industries
Provides technical expertise and support for shelf life solutions and aroma ingredients to the various laboratories of CFS located globally

Operational Revenue (INR Mn)

Work / Activities completed

Trial Runs were impacted due to the nationwide lockdown declared in March.
The plant was restarted on April 11, 2020, however operations remained impacted due to labour availability
The trials were again stopped due to the Blast in adjoining plant of Yashashvi Chemicals on June 3, 2020
Trial restarted on June 25, 2020 after the necessary repairs.
Trial runs are progressing swiftly.
Likely Commercial Production in Q2-FY21

Acquire 65% stake in Dresen Quimica SAPI De CV, Mexico in May 2016
Primarily manufactures Blends and Additives

Manufacturing Capacity / Year 12,000 MT

Key customer segments: Oil, Poultry, Diary, Rendering, Aqua, Pet food, Swine, Vitamin Pre-mix
Total Market size is ~USD 200 Mn and CFS Mexico enjoys an overall market share of ~15% giving enough growth opportunities
CFS Antioxidantes De Mexico S.A.de C.V, the holding company has been reversed merged with effect from February 1, 2019 into Dresen Quimica S.A.P.I de C.V, Mexico

Total Employee Strength 130+

Operational Revenue (INR Mn)

Shelf Life Solutions

Formed in 2013 for Blends and the production started in 2015
Has an application lab in Indaiatuba Brazil for customizing blends for Shelf-life Extension Solutions.
Handles distribution of bulk antioxidants and vanillin.
Key customer segments: Oil, Poultry, Diary, Rendering, Aqua, Pet food, Swine, Vitamin Pre-mix and Bio Diesel
Dedicated facility for animal feed and pet food additives.
Revenue will continue to grow due to launch of new products in animal nutrition and better penetration of markets

Operational Revenue (INR Mn)

CFS Wanglong

16 CFS North America

Shelf Life Solutions

• Formed in October 2015 as a wholly owned subsidiary

Market focus

Food Bulk oils (synthetic antioxidants), Meat & poultry (natural antioxidants)
Pet food Rendering for pet food (natural antioxidants), Rendering for animal feed (synthetic antioxidants)

Total Employee Strength 10+

Animal feed Antioxidants, Mould Inhibitors, Gut Health Probiotics, Others
Has launched new productsin natural anti-oxidants and animal nutrition
Built a strong diversified portfolio of 40+ products

Total Number of Customers 15+

Operational Revenue (INR Mn)

HISTORICAL FINANCIAL OVERVIEW

18 Historical Standalone Income Statement

Particulars (INR Mn)	FY18	FY19	FY20	Q1-FY21
Operational Income	4,050	5,481	5,798	1,212
Total Expenses	3,996	5,182	5,201	1,049
EBITDA	54	299	597	163
EBITDA Margin	1.33%	5.46%	10.30%	13.45%
Depreciation	91	91	113	31
Finance Cost	236	203	281	86
Other Income	92	137	241	10
Exceptional Items	-	-	31	5
PBT	(181)	142	413	51
Tax	(39)	35	106	13
Profit After Tax	(142)	107	307	38
PAT Margin	NA	1.95%	5.29%	3.14%
Other Comprehensive Income	1	(3)	(3)	-
Total Comprehensive Income	(141)	104	304	38
DilutedEPS (INR per share)	(1.63)	0.88	2.53	0.31

19 Standalone Balance Sheet

Particulars (INR Mn)	FY19	FY20	Particulars (INR Mn)	FY19	FY20
EQUITY	3,474	3,768	Non-Current Assets	2,733	3,802
a) Equity Share Capital	121	121	a) Property, Plant and Equipment	789	686
b) Other Equity	3,353	3,647	b) Capital Work In Progress	523	1,742
c) Non-Controlling Interest	-	-	c)Right-Of-Use Assets	-	246
			d) Investment Property	21	21
LIABILITIES	1,149	1,240	e) Other Intangible Assets	6	4
Non-Current Liabilities			f) Intangible Assets under Development	161	240
Financial Liabilities			g) Financial Assets
a) Borrowings	1,111	1,130	(i) Investments	657	740
b) LeaseLiabilities	-	50	(ii) Loans	288	36
b) Provisions	24	28	(iii) Other Financial Assets		-
c) Deferred Tax Liabilities (Net)	-	21	h) Deferred tax assets (Net)	12	-
d) Other Non-Current Liabilities	14	11	i) Income Tax Assets	36	33
			j) Other Non-Current assets	240	54
Current Liabilities	3,187	3,905	Current Assets	5,075	5,112
a) Financial Liabilities			a) Inventories	1,093	972
(i) Borrowings	1,990	2,184	b) Financial Assets
(ii) Trade Payables	1,059	1,330	(i) Investments	33	-
(iii) Other Financial Liabilities	115	250	(ii) Trade Receivables	2,619	3,235
(iv) Lease Liabilities	-	10	(iii) Cash and Cash Equivalents	189	7
b) Other Current Liabilities	15	61	(iv) Other Bank balances	502	124
c) Provisions	3	4	(v) Loans	159	301
d) Current Tax Liabilities (Net)	3	66	(vi) Other financial assets	221	235
			c) Other Current Assets	259	237
			d) Asset held for Sale
GRAND TOTAL -EQUITIES & LIABILITES	7,808	8,913	GRAND TOTAL –ASSETS	7,808	8,913

20 Historical Consolidated Income Statement

PARTICULARS (INR Mn)	FY18	FY19	FY20	Q1-FY21
Operational Income	7,228	8,922	10,491	3,057
Total Expenses	7,073	8,235	9,184	2,547
EBITDA	155	687	1,307	510
EBITDA Margin	2.14%	7.70%	12.46%	16.68%
Depreciation	267	290	328	95
Finance Cost	284	367	431	105
Other Income	86	138	34	5
Income from Associate	2	(1)	-	-
PBT	(308)	167	582	315
Tax	(68)	137	284	109
Profit After Tax	(240)	30	298	206
PAT Margin	-	0.34%	2.84%	6.74%
Other Comprehensive Income	124	5	13	46
Total Comprehensive Income	(116)	35	311	252
Diluted EPS (INR per share)	(3.01)	0.05	2.5	1.27

21 Consolidated Balance Sheet

PARTICULARS (INR Mn)	FY19	FY20	PARTICULARS (INR Mn)	FY19	FY20
EQUITY	4,303	4,601	Non-Current Assets	4,143	5,591
a) Equity Share Capital	121	121	a) Property, Plant and Equipment	2,055	2,034
b) Other Equity	3,588	3,910	b) Capital Work In Progress	573	1,761
c) Non-Controlling Interest	594	570	c) Right-Of-Use Assets	-	338
			d) Investment Property	21	21
			e) Goodwill	444	444
LIABILITIES			f) Other Intangible Assets	205	221
Non-Current Liabilities	1,961	2,261	g) Intangible Assets under Development	17	27
Financial Liabilities			h) Investment in Associate	1	1
a) Borrowings	1,936	2,115	i) Financial Assets
b) Lease Liabilities	-	97	(i) Investments	71	72
c) Provisions	24	28	(ii) Loans	111	123
d) Deferred Tax Liabilities (Net)	1	21	j) Deferred tax assets (Net)	412	407
			k) Income Tax Assets	74	66
			l) Other Non-Current assets	159	76
Current Liabilities	4,604	5,478	Current Assets	6,725	6,749
a) Financial Liabilities			a) Inventories	2,854	2,981
(i) Borrowings	2,443	2,781	b) Financial Assets
(ii) Trade Payables	1,646	1,737	(i) Investments	33	-
(iii) Lease liabilities	-	33	(ii) Trade Receivables	2,093	2,528
(iii) Other Financial Liabilities	366	672	(iii) Cash and Cash Equivalents	532	524
b)Other Current Liabilities	73	110	(iv) Other Bank balances	502	124
c) Provisions	71	79	(v) Loans	31	11
d)Current Tax Liabilities (Net)	5	66	(vi) Other financial assets	108	117
			c) Other Current Assets	572	464

GRAND TOTAL -EQUITIES & LIABILITES	10,868	12,340	GRAND TOTAL –ASSETS	10,868	12,340

Net Debt to Equity

Net Worth (INR Mn)

*As per I-GAAP

Share Price Data as on 30th June, 2020

Price Data (30thJune, 2020)	INR
Face Value	1.00
Market Price	52.5
52 Week H/L	89.9/33.4
Market Cap (Mn)	6,365.8
Equity Shares Outstanding (Mn)	121.2
1 Year Avg Trading Volume ('000)	447.9

Shareholding Pattern as on 30th June, 2020

Camlin Fine Sciences Limited

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of Camlin Fine Science Limited, which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.

For further details please contact our Investor Relations Representatives: VALOREM ADVISORS Mr. Anuj Sonpal Tel: +91-22-49039500 Email: [email protected]

AI assistant

Camlin Fine Sciences Ltd Investor Presentation 2020